Our study showed that B cells are a major source of therapy resistance under both innate and acquired immune response activated by STING agonist and ICB treatment, and identified that combining STING agonist with B-cell targeting and anti-TIM-1 ICB can improve the treatment response in murine HCC. Here, HAVCR1 is linked to hepatocellular carcinoma.